Your browser doesn't support javascript.
loading
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.
Kumar, S K; Dimopoulos, M A; Kastritis, E; Terpos, E; Nahi, H; Goldschmidt, H; Hillengass, J; Leleu, X; Beksac, M; Alsina, M; Oriol, A; Cavo, M; Ocio, E M; Mateos, M V; O'Donnell, E K; Vij, R; Lokhorst, H M; van de Donk, N W C J; Min, C; Mark, T; Turesson, I; Hansson, M; Ludwig, H; Jagannath, S; Delforge, M; Kyriakou, C; Hari, P; Mellqvist, U; Usmani, S Z; Dytfeld, D; Badros, A Z; Moreau, P; Kim, K; Otero, P R; Lee, J H; Shustik, C; Waller, D; Chng, W J; Ozaki, S; Lee, J-J; de la Rubia, J; Eom, H S; Rosinol, L; Lahuerta, J J; Sureda, A; Kim, J S; Durie, B G M.
Affiliation
  • Kumar SK; Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
  • Dimopoulos MA; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Kastritis E; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Terpos E; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Nahi H; Division of Hematology, Karolinska Institutet, Karolinska University Hospital at Huddinge, Stockholm, Sweden.
  • Goldschmidt H; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
  • Hillengass J; Department Med. V, University Hospital Heidelberg, Heidelberg, Germany.
  • Leleu X; Department Med. V, University Hospital Heidelberg, Heidelberg, Germany.
  • Beksac M; Oncologie hematologique et therapie cellulaire, chu de poitiers, Poitiers, France.
  • Alsina M; Department of Hematology, Ankara University School of Medicine, Ankara, Turkey.
  • Oriol A; Hematologic Malignancies Program, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Cavo M; Department of Hematology, Skane University Hospital, Malmö, Sweden.
  • Ocio EM; Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
  • Mateos MV; Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), Salamanca, Spain.
  • O'Donnell EK; Department of Hematolgy, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Vij R; Massachusetts General Hospital, Boston, MA.
  • Lokhorst HM; Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.
  • van de Donk NWCJ; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
  • Min C; VU University Medical Center, Amsterdam, The Netherlands.
  • Mark T; Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, The Republic of Korea.
  • Turesson I; Weill Cornell Medical College, New York, NY, USA.
  • Hansson M; Department of Hematology, Skane University Hospital, Malmö, Sweden.
  • Ludwig H; Department of Hematology, Skåne University Hospital, Lund University, Lund, Sweden.
  • Jagannath S; Department of Medicine, Center of Oncology, Hematology and Palliative Care, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.
  • Delforge M; Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Kyriakou C; Myeloma Study Group, Belgian Hematological Society, Brussels, Belgium.
  • Hari P; Department of Haematology, North West London NHS Trust, NPH Hospital, London, UK.
  • Mellqvist U; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Usmani SZ; Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Dytfeld D; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC, USA.
  • Badros AZ; Department of Hematology and Bone Marrow Transplantation, University of Medical Sciences in Poznan, Poland, Poznan, Poland.
  • Moreau P; Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Kim K; Department of Hematology, Nantes University Hospital, Nantes, France.
  • Otero PR; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, The Republic of Korea.
  • Lee JH; Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
  • Shustik C; Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, The Republic of Korea.
  • Waller D; Division of Haematology, McGill University Health Center, Montreal, QC, Canada.
  • Chng WJ; McGill University, Montreal, QC, Canada.
  • Ozaki S; Department of Haematology-Oncology, National University Health Systems, Singapore.
  • Lee JJ; Department of Hematology, Tokushima Prefectural Central Hospital, Tokushima, Japan.
  • de la Rubia J; Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, The Republic of Korea.
  • Eom HS; Hospital Dr. Peset, Valencia, Spain.
  • Rosinol L; HematologicOncology Clinic, Center for Specific Organs, National Cancer Center, Goyang, South Korea.
  • Lahuerta JJ; Department of Hematology, Hospital Clinic iProvincial, Barcelona, Spain.
  • Sureda A; Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Kim JS; Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain.
  • Durie BGM; Yonsei University College of Medicine, Severance Hospital, Seoul, The Republic of Korea.
Leukemia ; 31(11): 2443-2448, 2017 11.
Article in En | MEDLINE | ID: mdl-28620163
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Adjuvants, Immunologic / Proteasome Inhibitors / Multiple Myeloma Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2017 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Adjuvants, Immunologic / Proteasome Inhibitors / Multiple Myeloma Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2017 Type: Article